Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0950 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0850 - 0.1000 |
| 52 Week Range | 0.0050 - 0.1350 |
| Volume | |
| Avg. Volume | 28,890 |
| Market Cap | 8.928M |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Aug 27, 2024 - Sept 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRakovina Therapeutics Provides Update on Previously Announced Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024 and July 19, 2024, the Company has received subscriptions for an aggregate of $2,000,000 worth of units o
- GlobeNewswire
Rakovina Therapeutics Announces Second Upsizing of Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press releases dated May 23, 2024 and June 20, 2024, that to accommodate additional indications of interest it will upsize the previously announce
- GlobeNewswire
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press release dated May 23, 2024, that it has received subscriptions totalling $1.7 million for its previously announced $1.5 million private placeme
